Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

A 'homing beacon' for cancer drugs

Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. If scientists could put a “homing beacon” in tumors, they could attract these medicines and reduce side effects caused by the drugs acting on healthy cells.

17 Jun 2019

Patients with advanced Hodgkin's lymphoma may benefit from radiotherapy after chemotherapy

Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy even when all traces of the cancer appear to have gone, according to late breaking results presented at the ESTRO 38 conference today.

29 Apr 2019

Study finds no statistically significant effect of drug shortages on cancer treatment

For the vast majority of cancer drugs experiencing shortages over a seven-year period, a new USC research study found no statistically significant effect of shortages on chemotherapy treatment.

8 Apr 2019

A very old antibiotic shows promise in treating fatal form of breast cancer

Of the three major subtypes of breast cancer, the &laquotriple negative» is the most lethal: half of all breast cancer deaths are attributed to it, whereas it accounts for only about 15% of incidences of breast cancer.

28 Mar 2019

Early marker of cardiac damage triggered by cancer treatment identified

Every year, 4 million new cases of cancer are diagnosed in Europe. Advances in cancer treatment sometimes come at the cost of major adverse effects, and one of the most prominent is cardiotoxicity. Myocardial toxicity affects as many as 25% of patients undergoing treatment with commonly used anticancer drugs.

19 Feb 2019

New breakthrough study can impact drug development and personalized medicine

A breakthrough for brain tumor drug development and personalized medicine published today in Nature Scientific Reports.

6 Feb 2019

New study compares chemotherapy drugs with development of cardiomyopathy

In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes.

1 Feb 2019

Preparation, characterization of Soyasapogenol B loaded onto functionalized MWCNTs

Multi-Walled Carbon Nanotubes is the name that is derived from their structure and walls are formed by one atom thick sheet of carbon.

17 Jan 2019

Study uncovers how tumors backfire on neoadjuvant chemotherapy

Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove.

2 Jan 2019

Soyasapogenol B: A new drug delivery technology for therapeutics

Multi-Walled Carbon Nanotubes (MWCNTs) are characterized by walls formed by a one atom thick sheet of carbon.

24 Dec 2018

New nanoscale technique developed to get more information from the blood of cancer patients

A technique to get more information from the blood of cancer patients than previously possible has been developed.

28 Nov 2018

Novel DNA nanoplatform delivers anticancer agents to multidrug-resistant tumors

One of the most successful techniques to combat multidrug resistance in cancer cells is the downregulation of those genes responsible for drug resistance.

22 Nov 2018

Mannose - nutritional supplement, could slow some cancers

Mannose is a sugary nutritional supplement that has shown promise in slowing down the growth of certain cancers in laboratory mice. The results of the five year-long study from Glasgow were published in the latest issue of the journal Nature.

21 Nov 2018

Nutritional supplement can slow cancer growth and enhance effects of chemotherapy

Mannose sugar, a nutritional supplement, can both slow tumor growth and enhance the effects of chemotherapy in mice with multiple types of cancer.

21 Nov 2018

Sugar supplement shown to slow tumor growth and enhance chemotherapy

Mannose, a type of sugar, has been shown to slow tumor growth and enhance chemotherapy in mouse models of certain cancers.

21 Nov 2018

CDK2 protein plays key role in heart damage caused by doxorubicin, finds study

A new study by Washington State University researchers suggests that a protein called CDK2 plays a critical role in heart damage caused by doxorubicin, a commonly used chemotherapy drug.

8 Nov 2018

Promising potential of stimuli-responsive nanomaterial for cancer therapy

Nanosystems that deliver anticancer drugs or imaging materials to tumors are showing significant progress, particularly those that respond to tumor-related stimuli, according to a review published in the journal Science and Technology of Advanced Materials.

30 Oct 2018

SLU researcher seeks to find solutions for 'chemo brain' symptoms and side effects of opioids

With a pair of RO1 grants from the National Institutes of Health, pain researcher Daniela Salvemini, Ph.D., will embark on two new research projects, studying chemotherapy-induced cognitive impairment, or "chemo brain," symptoms and unwanted side effects of opioids.

23 Oct 2018

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Sarcoma patients show great openness to the use of complementary alternative medicines (CAMs) for supportive care, but they are poorly informed about safety issues and risk of interactions with anti-cancer drugs, a study to be presented at ESMO 2018 reported.

10 Oct 2018

Study: Chemotherapy drugs may promote muscle mitochondrial dysfunction

Chemotherapy drugs to treat breast cancer may promote muscle mitochondrial dysfunction, according to new research. Dysfunctional mitochondria, the energy centers of the cells, may contribute to fatigue and weakness that some people with breast cancer experience through the course of disease treatment.

5 Oct 2018